Biotechnology Business

BioCryst Appoints Elliott T. Berger, Ph.D., Senior Vice President of Regulatory Affairs

Published in Medical Letter on the CDC and FDA, August 26th, 2007

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced that Elliott T. Berger, Ph.D., has joined the company's senior management team as Senior Vice President of Regulatory Affairs. Dr. Berger brings to BioCryst a long and successful track record in obtaining approval from the U.S. Food and Drug Administration (FDA) for numerous drugs.

"Dr. Berger brings distinguished regulatory affairs credentials to BioCryst at a key time when our pipeline is most promising," said Jon P. Stonehouse, Chief Executive Officer of BioCryst. "Elliott's breadth of experience in clinical development and regulatory affairs will be a valuable asset as we take our late-stage compounds through...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2007-08-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry